Video

Dr. Advani Discusses Front-Line Brentuximab

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, discusses the movement of brentuximab vedotin combined with CHOP to the front-line.

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, discusses the movement of brentuximab vedotin combined with CHOP to the front-line.

Brentuximab is currently approved for Hodgkin lymphoma and anaplastic large cell lymphoma. Brentuximab vedotin will not be beneficial for all subtypes of lymphoma, Advani says, but will be for CD30-positive lymphomas. This is an exciting potential development because about 30% of other T-cell lymphomas also express CD30.

Advani looking forward to the large randomized trial evaluating CHOP chemotherapy plus placebo compared to CHOP plus brentuximab.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine